Authors: Bernhard Scher Michael Seitz Wolfram Albinger Reinhold Tiling Michael Scherr HansChristoph Becker Michael Souvatzogluou FranzJosef Gildehaus HansJürgen Wester Stefan Dresel
Publish Date: 2006/08/24
Volume: 34, Issue: 1, Pages: 45-53
Abstract
The value and limitations of 11Ccholine PET and PET/CT for the detection of prostate cancer remain controversial The aim of this study was to investigate the diagnostic efficacy of 11Ccholine PET and PET/CT in a large group of patients with suspected prostate cancerFiftyeight patients with clinical suspicion of prostate cancer underwent 11Ccholine PET 25/58 Siemens ECAT Exact HR+ or PET/CT 33/58 Philips Gemini scanning On average 500 MBq of 11Ccholine was administered intravenously Studies were interpreted by raters blinded to clinical information and other diagnostic procedures Qualitative image analysis as well as semiquantitative SUV measurement was carried out The reference standard was histopathological examination of resection specimens or biopsyPrevalence of prostate cancer in this selected patient population was 638 37/58 11Ccholine PET and PET/CT showed a sensitivity of 865 32/37 and a specificity of 619 13/21 in the detection of the primary malignancy With regard to metastatic spread PET showed a perpatient sensitivity of 818 9/11 and produced no false positive findingsBased on our findings differentiation between benign prostatic changes such as benign prostatic hyperplasia or prostatitis and prostate cancer is feasible in the majority of cases when image interpretation is primarily based on qualitative characteristics SUVmax may serve as guidance False positive findings may occur due to an overlap of 11Ccholine uptake between benign and malignant processes By providing functional information regarding both the primary malignancy and its metastases 11Ccholine PET may prove to be a useful method for staging prostate cancer
Keywords: